Imbruvica® (ibrutinib)
for Leukemia

Imbruvica (ibrutinib) is a targeted therapy used to treat chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenström’s macroglobulinemia (WM), and chronic graft versus host disease (cGVHD) in certain patients. It works by inhibiting Bruton tyrosine kinase (BTK), a key enzyme in pathways that promote cancer cell growth. Additionally, it reduces B cell activation and growth, making it effective in treating cGVHD.

Heart
Medication Guide Icon Medication Guide
TV Commercial Icon TV Commercial
Patient Website Icon Patient Website
Efficacy Data Icon Efficacy Data
New Articles Icon New Articles
Savings and Support Icon Savings and Support
Company MD Payments Icon Company MD Payments
Clinical Trials Icon Clinical Trials
Adverse Event Report Icon Adverse Event Report
Other top medicines used to treat Leukemia